Crizotinib hydrochloride
CAS No. 1415560-69-8
Crizotinib hydrochloride ( PF-02341066 hydrochloride;PF-2341066 hydrochloride )
产品货号. M11726 CAS No. 1415560-69-8
Crizotinib (PF-02341066;PF-2341066)is a potent, selective, orally bioavailable, ATP-competitive inhibitor of c-Met catalytic activity with Ki of 4 nM.
纯度: >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
规格 | 价格/人民币 | 库存 | 数量 |
5MG | ¥251 | 有现货 |
|
10MG | ¥389 | 有现货 |
|
25MG | ¥608 | 有现货 |
|
50MG | ¥818 | 有现货 |
|
100MG | ¥1134 | 有现货 |
|
200MG | ¥1409 | 有现货 |
|
500MG | ¥1936 | 有现货 |
|
1G | 获取报价 | 有现货 |
|
生物学信息
-
产品名称Crizotinib hydrochloride
-
注意事项本公司产品仅用于科研实验,不得用于人体或动物的临床与诊断
-
产品简述Crizotinib (PF-02341066;PF-2341066)is a potent, selective, orally bioavailable, ATP-competitive inhibitor of c-Met catalytic activity with Ki of 4 nM.
-
产品描述Crizotinib (PF-02341066;PF-2341066)is a potent, selective, orally bioavailable, ATP-competitive inhibitor of c-Met catalytic activity with Ki of 4 nM; displays >1,000-fold selective for the VEGFR2 and PDGFRβ RTKs, >250-fold selective for IRK and Lck, and ~40- to 60-fold selective for Tie2, TrkA, and TrkB; also inhibits ALK (IC50=24 nM), potently inhibits c-Met phosphorylation and c-Met-dependent proliferation, migration, or invasion of human tumor cells in vitro (IC50=5-20 nM); shows antitumor efficacy in tumor models at well-tolerated doses in vivo.Lung Cancer Approved
-
同义词PF-02341066 hydrochloride;PF-2341066 hydrochloride
-
通路Angiogenesis
-
靶点ALK
-
受体ALK
-
研究领域Cancer
-
适应症Lung Cancer
化学信息
-
CAS Number1415560-69-8
-
分子量486.80
-
分子式C21H23Cl3FN5O
-
纯度>98% (HPLC)
-
溶解度DMSO: ≥ 4.6 mg/mL
-
SMILESCC(C1=C(C=CC(=C1Cl)F)Cl)OC2=C(N=CC(=C2)C3=CN(N=C3)C4CCNCC4)N.Cl
-
化学全称2-Pyridinamine, 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-[1-(4-piperidinyl)-1H-pyrazol-4-yl]-, hydrochloride (1:1)
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1. Zou HY, et al. Cancer Res. 2007 May 1;67(9):4408-17.
2. Christensen JG, et al. Mol Cancer Ther. 2007 Dec;6(12 Pt 1):3314-22.
3. Knowles LM, et al. Clin Cancer Res. 2009 Jun 1;15(11):3740-50.
2. Christensen JG, et al. Mol Cancer Ther. 2007 Dec;6(12 Pt 1):3314-22.
3. Knowles LM, et al. Clin Cancer Res. 2009 Jun 1;15(11):3740-50.
产品手册
关联产品
-
ASP3026
ASP3026 is a potent small molecule ALK inhibitor with IC50 of 3.5, 10, 5.4 and 6.8 nM for wt ALK, ALK F1174L, ALK R1275Q and NPM1-ALK, respectively.
-
SB-505124
SB505124 is a selective inhibitor of TGFβR for ALK4, ALK5 with IC50 of 129 nM and 47 nM in cell-free assays, respectively, also inhibits ALK7, but does not inhibit ALK1, 2, 3, or 6.
-
TPX 0005
TPX 0005 (Ropotrectinib, Repotrectinib, TPX0005) is a novel ALK/ROS1/TRK inhibitor.